Naveed Sattar graduated in Medicine from the University of Glasgow, Scotland, in 1990, where he was also awarded his PhD in 1998. In 2005, he was appointed Professor of Metabolic Medicine at the Institute of Cardiovascular and Medical Sciences (now called School of Cardiovascular and Metabolic Health). He is also an Honorary Consultant in Metabolic Medicine at the Glasgow Royal Infirmary, where he co-leads a cardiovascular prevention clinic. 

Professor Sattar’s research focuses on prevention and management of diabetes, obesity and cardiovascular disease. He is currently involved in several lifestyle and drug trials in diabetes and cardiovascular disease (including cardiovascular outcome trials) and leads on biomarker initiatives in other outcome trials.  He is also involved in several COVID-19-related projects.

Many of Professor Sattar’s findings have been incorporated into clinical guidelines and he has served on national and international guideline committees, including: the European Society of Cardiology (ESC) Task Force to develop 2023 guidelines on diabetes and cardiovascular diseases (CVD); Joint British Societies guidelines on prevention of CVD in clinical practice; SIGN obesity and CVD prevention guidelines (as Chair); and European CVD prevention guidelines. He is one of the world’s most cited academics (in the top 1% of the field in clinical medicine) and has authored or co-authored over 1000 published papers, with over 190,000 citations (Google Scholar, March 2023). He is on the editorial board for BMC Medicine and is an Associate Editor for Diabetes Care.

Professor Sattar has spoken at numerous meetings in the UK and globally and has been the recipient of several prizes for his research. These include the Banting Memorial Lecture in 2023, the Rank Nutrition Lecture in 2018, the Minkowski Award Lecture in 2011, the Dorothy Hodgkin Lecture, the John French Lecture and the RD Lawrence Lecture. He presented the prestigious Camillo Golgi Prize lecture at the European Association for the Study of Diabetes (EASD) annual meeting in 2020. In 2016, he was elected a fellow of the Academy of Medical Sciences. He is also a Fellow of the Royal College of Pathologists, the Royal College of Physicians and Surgeons of Glasgow and the Royal Society of Edinburgh.  He has supervised 16 successful MDs/PhDs, including one awarded the Bellahouston Prize for the best thesis in medicine over the year.  He has also led or developed training courses for under- and postgraduate students and contributes to teaching at multiple levels.

Duality of Interest: Professor Sattar has received research support / grants from Astra Zeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics and speaker’s fees/honoraria from Astra Zeneca, Boehringer Ingelheim, Eli Lilly and Novo Nordisk. He has also received payments for membership of boards/advisory panels from Amgen, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Pfizer and Roche Diagnostics together with consultancy fees from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. 

Date: Spring 2023